Fig. 1. Example of patients from groups A, B, and C. (A) An example of a patient from group A, a 47-year-old female with systemic lupus erythematosus (SLE). The patient had taken a total dose of 1,796.2 mg of hydroxychloroquine (HCQ; daily dose of 200 mg), with a body weight of 57.35 kg. Significant thinning of choroidal thickness (ChT) in all measured areas and thinning of the outer nuclear layer (ONL) in the superior inner, superior outer, temporal outer, and nasal outer areas can be observed (the darker red area represents the ONL thinning area). (B) An example of a patient from group B, a 50-year-old female with SLE. The patient had taken a total dose of 1,350.7 mg of HCQ (daily dose of 100 mg) and had been on medication for 6 years before discontinuing due to decreased renal function. The patient showed recovery of ChT, but ONL thickness continued to decrease. (C) An example of a patient from group C, a 51-year-old female with SLE. The patient had taken a total dose of 1,470.4 mg of HCQ (daily dose of 200 mg) and had been on medication for 15 years before discontinuing due to HCQ retinopathy. Thinning of both ChT and ONL thickness at baseline can be observed.

J Retin 2024;9:62-72 https://doi.org/10.21561/jor.2024.9.1.62

© 2024 J Retin